Structured intelligence coverage

Structured records are temporarily unavailable. The published profile and its source ledger remain accessible.

Identity checks do not refresh the age of governance evidence. Open a record for its source date and review state.

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
11 current organization shown on this profile
Board positions
Not establishedNo board position is currently listed on this profile
Committee roles
Not establishedNo committee role is currently confirmed by the cited sources
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Extensive background in hematology/oncology and rare disease drug development with 10 years at Blueprint Medicines. Led regulatory approvals for multiple drugs including AYVAKIT, GAVRETO, CERDELGA and MOZOBIL. Holds MBA from Boston University and B.Sc. in Chemistry from University of British Columbia.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Executive appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Committee appointments across companies · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Connections

Explore the roles, education and affiliations published in this record.

Damora Therapeutics, Inc.

Open Damora Therapeutics, Inc. profile →

Chief Operating Officer at Damora Therapeutics, Inc.

Start not stated → End not stated

current · source reported

Observed: 2026-09-25

Damora Therapeutic…Damora Therapeutics, Inc.Sherwin Sattarzadeh

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingGLTO DEF 14A executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Technology background.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:sherwin-sattarzadeh
Record version
public-0

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. GLTO DEF 14A executive officers

    sec filing · Source published: Apr 29, 2026 · Retrieved: Jul 28, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Galecto, Inc. · Claim reviewed: Jul 28, 2026
    • Executive title: Executive title: Chief Operating Officer · Claim reviewed: Sep 6, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  2. DMRA DEF 14A executive officers

    sec filing · Source published: Apr 29, 2026 · Retrieved: May 16, 2026

    Supports 2 claims
    • Executive company: Executive at Galecto, Inc. · Claim reviewed: Jul 28, 2026
    • Executive title: Executive title: Chief Operating Officer · Claim reviewed: Sep 6, 2026

  3. Open source

    sec def 14a · Source published: Apr 29, 2026 · Retrieved: Sep 6, 2026

    Supports 2 claims
    • Professional Role: Chief Operating Officer at Damora Therapeutics, Inc. · Claim reviewed: Sep 6, 2026
    • Executive title: Executive title: Chief Operating Officer · Claim reviewed: Sep 6, 2026

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · Source reportedAI and ML experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 28, 2026

Cybersecurity experience · Source reportedCybersecurity experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 28, 2026

Executive company · CorroboratedExecutive at Galecto, Inc.Supported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
Jul 28, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 28, 2026

Executive title · CorroboratedExecutive title: Chief Operating OfficerSupported by 3 public records3 sources
Verification
Corroborated
Confidence
95%
Last reviewed
Sep 6, 2026
Technology background · Source reportedTechnology background: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 28, 2026

View all sources3 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 28, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Technology background

  2. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: Executive company · Executive title

  3. https://www.sec.gov/Archives/edgar/data/1800315/000119312526191429/dmra-20260429.htm

    Sec Def 14a · Tier not stated · Reviewed Sep 6, 2026

    Supports: Chief Operating Officer at Damora Therapeutics, Inc. (NASDAQ: DMRA) · Executive title